TransEnterix, Inc. (NYSEAMERICAN:TRXC) dropped 7.4% during trading on Tuesday . The company traded as low as $0.63 and last traded at $0.63, approximately 2,201,245 shares were traded during mid-day trading. A decline of 15% from the average daily volume of 2,597,942 shares. The stock had previously closed at $0.68.
TRXC has been the topic of a number of recent research reports. Zacks Investment Research downgraded TransEnterix from a “hold” rating to a “sell” rating in a research note on Saturday, July 13th. Royal Bank of Canada downgraded TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 target price on the stock. in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $2.62.
TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $3.64 million during the quarter, compared to the consensus estimate of $5.13 million.
About TransEnterix (NYSEAMERICAN:TRXC)
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Featured Story: Strangles
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.